Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers

Urological Research

Volumn 26, Issue 3, 1998, Pages 161-164

  Okamura, Takehiko ^a,b   Akita, Hidetoshi ^a   Kawai, Noriyasu ^a   Tozawa, Keiichi ^a   Yamada, Yasuyuki ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Meijo Hospital   (Japan)

Author keywords

BCG; Bcl 2; Recurrence; Superficial bladder cancer

Indexed keywords

BCG VACCINE; CYCLINE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DRUG INSTILLATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SUPERFICIAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0031747149     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400050040     Document Type: Article

References (21)

1. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K (1995) Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder Cancer 75:552
2. Cookson MS, Sarosdy MF (1992) Management of stage Tl superficial bladder cancer with mtravesical bacillus CalmetteGuerin therapy. J Urol 148:797
3. Cordon-Cardo C, Finstad CL, Bander NH, Melamed MR (1987) Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract Am J Pathol 126:269
4. Daas M, del Rosario AD, Bui HX, Singh JK, Ross JS (1995) Bcl-2 protein expression is related to cellular differentiation in urinary bladder transitional cell carcinoma (UB-TCC). Presented at U.S. and Canadian Academy of Pathology. Toronto
5. Esrig D, Spruck III CH, Nichois PW, Chaiwun B, Steven K, Groshen S, Chen S-C, Skinner DG, Jones PA, Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389
6. Glick SH, Howell LP, White RWD (1996) Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155:1754
7. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334
8. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE (1993) Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262:1274
9. Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, Ratliff TL, Catalona WJ (1988) Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 139:935
10. King ED, Matteson J, Jacobs SC, Kyprianou N (1996) Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression J Urol 155:316
11. Lipponen PK, Aaltomaa S (1994) Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173:333
12. Masuda M, Takano Y. Iki M, Asakura T, Hashiba T, Noguchi S. Hosaka M (1997) Apoptosis in transitional cell carcinoma of the renal pelvis and ureter: association with proliferative activity, bcl-2 expression and prognosis. J Urol 158:750
13. Ogura K, Habuchi T, Yamada H, Ogawa O, Yoshida O (1995) Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer:positive immunostaining and radiosensitivity. Int J Urol 2:302
14. Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K, Kohri K (1996) Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing the recurrence of initially resistant superficial bladder cancers. J Urol 156:967
15. Olaetxea EB, Belloso L, Tamayo JG (1996) Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor. Eur J Cancer 32A:444
16. Sarosdy MF, Lamm DL (1989) Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol 142:719
17. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK. Jonas U (1995) p53 immunohistochemistry as independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201
18. Shiina H, Igawa M, Yagi H, Urakami S, Shirakawa H, Ishibe T (1996) Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. Eur Urol 30:80
19. Shima H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T (1996) Immunohistochemistry of p53 protein in transitional cell carcinoma of the bladder using an image analyzer. Oncology 53:233
20. Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P (1996) Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155:1784
21. Vet JAM, Witjes JA, Marras SAE, Hessels D, van der Poel HG, Debruyne FMJ, Schalken JA (1996) Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res 2:1055